Sarepta Therapeutics Growth, Revenue, Number of Employees and Funding


Boston, MA USA
Total Funding:$261.8M
Lead Investor(s):Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Sarepta Therapeutics's estimated revenue is currently $301M per year.
  • Sarepta Therapeutics received $375.0M in venture funding in November 2017.
  • Sarepta Therapeutics's estimated revenue per employee is $396619
  • Sarepta Therapeutics's total funding is $261.8M.

Employee Data

  • Sarepta Therapeutics has 759 Employees.
  • Sarepta Therapeutics grew their employee count by 50% last year.
  • Sarepta Therapeutics currently has 1 job openings.

Executive Contacts

Ty HowtonSVP General Counsel & Corporate secretary
Ni SunAssociate Director, Regulatory strategy
Hemchand SookdeoExecutive Director, Program Management
Lixin HanExecutive Director, Biometrics
Ryan BrownVP, Chief Compliance Counsel and Officer
Elaine MarshallDirector, QA Compliance
Pat CoganSenior Director, Financial Planning & Analysis
Alex BushAssociate Director, Regulatory Strategy
Joy HaughAssociate Director-Safety Scientist
Joseph RutkowskiSenior Director, R&D Pharmacology/Toxicology

What Is Sarepta Therapeutics?

Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare diseases. Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in Limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth (CMT) and CNS-related disorders, reaching a total of over 20 therapies in various stages of development. The Company's programs span across several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is poised to be the most meaningful precision genetic medicine company in the world and make a profound difference in the lives of patients suffering from rare neuromuscular diseases and other rare diseases. For more information, please visit



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ohana Bioscienc...
Tango Therapeut...
Compass Therape...
Hamilton Storag...
Alnylam Pharmac...
Berkshire Corpo...
Repligen Corpor...
Allena Pharmace...
ABclonal Techno...

Sarepta Therapeutics News

09/03/2019 - Here's Why Sarepta Therapeutics Dropped 39.4% in August

Shares of Sarepta Therapeutics (NASDAQ: SRPT) fell more than 39% last month, according to data provided by S&P Global Market Intelligence ...

09/08/2019 - Charles Schwab Investment Management Inc. Grows Stock Holdings in Sarepta Therapeutics Inc (NASDAQ:SRPT)

Charles Schwab Investment Management Inc. grew its holdings in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 8.9% in the 2nd ...

09/03/2019 - Sarepta Therapeutics, Inc. (SRPT): Average 1-Day Percentage Change on Earnings

32 days have passed by since the last earnings report for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) and the new quarterly results look set to ...

Sarepta Therapeutics Funding

DateAmountRoundLead InvestorsReference
2002-03-27$22.0MPrivate Equity FinaArticle
2003-05-06$15.0MPrivate PlacementArticle
2003-12-05$15.0MEquity PlacementArticle
2005-11-15$22.6MUndisclosedRodman and Renshaw LLCArticle
2009-02-04$16.5MUndisclosedEastbourne Capital ManagementArticle
2009-08-21$30.0MUndisclosedJefferies & Company IncArticle
2011-04-04$30.0MUndisclosedLazard Capital Markets LLC, Piper Jaffray & CoArticle
2015-06-30$40.0MUndisclosedMidcap FinancialArticle
2015-10-07$127.0MUndisclosedCredit SuisseArticle
2016-06-10$37.5MUndisclosedCredit SuisseArticle
2016-09-23$225.0MUndisclosedJ.P. MorganArticle
2016-09-26$300.0MUndisclosedJ.P. MorganArticle
2017-07-25$287.5MUndisclosedGoldman Sachs & Co. LLCArticle

Sarepta Therapeutics Executive Hires

2005-01-20Joseph HornVP CardiologyArticle
2007-03-29Jack L. BowmanChairmanArticle
2008-02-12Leslie HudsonCEOArticle
2008-07-29J. David BoyleSVP/CFOArticle
2008-07-31Mark WebberGeneral Manager Finance/AdministrationArticle
2009-05-19Paul MedeirosChief Business Officer/VP Business DevArticle
2010-04-23David BoyleInterim President/CEO/CFOArticle
2010-12-14Chris GarabedianCEO/PresidentArticle
2011-03-29Peter S. LinsleyChief Scientific OfficerArticle
2012-11-06Sandesh MahatmeCFO/SVPArticle
2014-01-10Art KriegSVP/Chief Scientific OfficerArticle
2014-08-01John HodgmanInterim chairmanArticle
2015-04-02Edward KayeInterim CEO/CMOArticle
2015-07-02Henri TermeerAdvisorArticle
2017-06-29Douglas IngramPresident/CEOArticle
2017-09-26Guriqbal BasiChief Scientific OfficerArticle
2018-06-05Louise Rodino-Klapacice president, gene therapy, overseeingArticle
2018-06-08Gilmore O?NeillChief Medical OfficerArticle

Sarepta Therapeutics New Location/Offices

2009-07-31Seattle, WAArticle
2014-06-03Boston, MAArticle
2017-07-07Boston, MAArticle

Sarepta Therapeutics Acquisitions

DateCompany NameAmountNotesReference
2019-02-28Myonexus Therapeutics IncArticle

Sarepta Therapeutics Staff Cuts

DateNumber of EmployeesLocationReference
2008-06-1116% of WorkforcePortland/Corvallis, OR/RTP, NCArticle
2009-08-0315 JobsArticle